AAAAAA

   
Results: 1-12 |
Results: 12
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma
Authors: Solorzano, CC Baker, CH Tsan, R Traxler, P Cohen, P Buchdunger, E Killion, JJ Fidler, IJ
Citation: Cc. Solorzano et al., Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma, CLIN CANC R, 7(8), 2001, pp. 2563-2572
Tyrosine kinase inhibitors: From rational design to clinical trials
Authors: Traxler, P Bold, G Buchdunger, E Caravatti, G Furet, P Manley, P O'Reilly, T Wood, J Zimmermann, J
Citation: P. Traxler et al., Tyrosine kinase inhibitors: From rational design to clinical trials, MED RES REV, 21(6), 2001, pp. 499-512
ATP site-directed competitive and irreversible inhibitors of protein kinases
Authors: Garcia-Echeverria, C Traxler, P Evans, DB
Citation: C. Garcia-echeverria et al., ATP site-directed competitive and irreversible inhibitors of protein kinases, MED RES REV, 20(1), 2000, pp. 28-57
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis (vol 43, pg 2316, 2000)
Authors: Bold, G Altmann, KH Frei, J Lang, M Manley, PW Traxler, P Wietfeld, B Bruggen, J Buchdunger, E Cozens, R Ferrari, S Furet, P Hofmann, F Martiny-Baron, G Mestan, J Rosel, J Sills, M Stover, D Acemoglu, F Boss, E Emmenegger, R Lasser, L Masso, E Roth, R Schlachter, C Vetterli, W Wyss, D Wood, JM
Citation: G. Bold et al., New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis (vol 43, pg 2316, 2000), J MED CHEM, 43(16), 2000, pp. 3200-3200
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
Authors: Bold, G Altmann, KH Frei, J Lang, M Manley, PW Traxler, P Wietfeld, B Bruggen, J Buchdunger, E Cozens, R Ferrari, S Furet, P Hofmann, F Martiny-Baron, G Mestan, J Rosel, J Sills, M Stover, D Acemoglu, F Boss, E Emmenegger, R Lasser, L Masso, E Roth, R Schlachter, C Vetterli, W Wyss, D Wood, JM
Citation: G. Bold et al., New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis, J MED CHEM, 43(12), 2000, pp. 2310-2323
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
Authors: Bruns, CJ Solorzano, CC Harbison, MT Ozawa, S Tsan, R Fan, D Abbruzzese, J Traxler, P Buchdunger, E Radinsky, R Fidler, IJ
Citation: Cj. Bruns et al., Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma, CANCER RES, 60(11), 2000, pp. 2926-2935
Synthesis of N-phenylpyrrole carboximides
Authors: Hubmann, D Liechti, C Trinks, U Traxler, P Sequin, U
Citation: D. Hubmann et al., Synthesis of N-phenylpyrrole carboximides, MOLECULES, 4(6), 1999, pp. 151-158
Preparation of 4-(4 '-hydroxyanilino)-5-anilinophthalimide and 4,5-bis-(4 '-hydroxyanilino)-phthalimide by microbial hydroxylation
Authors: Weidner, S Goeke, K Trinks, U Traxler, P Ucci-Stoll, K Ghisalba, O
Citation: S. Weidner et al., Preparation of 4-(4 '-hydroxyanilino)-5-anilinophthalimide and 4,5-bis-(4 '-hydroxyanilino)-phthalimide by microbial hydroxylation, BIOS BIOT B, 63(8), 1999, pp. 1497-1500
Strategies toward the design of novel and selective protein tyrosine kinase inhibitors
Authors: Traxler, P Furet, P
Citation: P. Traxler et P. Furet, Strategies toward the design of novel and selective protein tyrosine kinase inhibitors, PHARM THERA, 82(2-3), 1999, pp. 195-206
Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: Isoflavones and 3-phenyl-4(1H)-quinolones
Authors: Traxler, P Green, J Mett, H Sequin, U Furet, P
Citation: P. Traxler et al., Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: Isoflavones and 3-phenyl-4(1H)-quinolones, J MED CHEM, 42(6), 1999, pp. 1018-1026
A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitroand in vivo. (vol 76, pg 154, 1998)
Authors: Lydon, N Mett, H Mueller, M Becker, M Cozens, RM Daniels, D Traxler, P Buchdunger, E Stover, D
Citation: N. Lydon et al., A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitroand in vivo. (vol 76, pg 154, 1998), INT J CANC, 81(4), 1999, pp. 669-669
Tyrosine kinase inhibitors in cancer treatment (part II)
Authors: Traxler, P
Citation: P. Traxler, Tyrosine kinase inhibitors in cancer treatment (part II), EXPERT OP T, 8(12), 1998, pp. 1599-1625
Risultati: 1-12 |